Reading this on a mobile device? Try our optimized mobile version here:

June 7, 2012
What's your BIO? President & CEO Jim Greenwood shares his thoughts on the Keynote Sessions at the upcoming BIO International Convention on BIOtechNOW.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
Finally, Progress Reported in Treatment of Lung Cancer
Chicago – With five-year survival rates of 15 percent, lung cancer treatment is not, overall, one of oncology’s poster children. Partly, that’s due to the sheer genomic complexity of the disease and the disease, like its most frequent cause, smoking, comes with social stigma. Find out the details.

  Health Care & Policy 
  • ImmunoCellular and Tocagen develop novel drugs for brain cancer
    ImmunoCellular Therapeutics and Tocagen, in collaboration with MD Anderson Cancer Center in Houston, are individually developing treatments for glioblastoma multiforme, a brain cancer that killed Sen. Edward Kennedy. ImmunoCellular's experimental drug ICT-107 uses the immune system to attack tumors. Tocagen's Delta-24 uses modified viruses to attack cancer cells. Bloomberg Businessweek (6/6) LinkedInFacebookTwitterEmail this Story
  • Novartis' Ilaris cuts SJIA symptoms in late-stage study
    A Phase III trial found that 62% of patients with systemic juvenile idiopathic arthritis who received Novartis' Ilaris became free from symptoms, compared with 32% in the placebo group. The research also demonstrated that one-third of patients could end steroid intake within five months of using Ilaris, the drugmaker said. Reuters (6/6) LinkedInFacebookTwitterEmail this Story
  • Researchers map genome of Chagas' disease-carrying insect
    An international team of researchers has mapped the genome of Rhodnius prolixus, the most common species of insect that carries the Chagas' disease parasite in Central America. The findings, presented at a genomic and triatomine biology meeting, could lead to the discovery of methods to prevent disease transmission. The study is expected to be published within a year. (6/4) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Opko buys 45% of hepatitis B vaccine maker
    Opko Health agreed to buy a 45% stake in an Israeli firm that manufactures Sci-B-Vac, a recombinant mammalian cell vaccine for patients with hepatitis B who don't respond to traditional vaccines. The deal for the company, which shares the name Sci-B-Vac, is estimated to be worth a few million dollars. Globes (Israel) (6/6) LinkedInFacebookTwitterEmail this Story
  Industry Deals 
  • Merck KGaA and Dr. Reddy's to co-develop biosimilars
    Merck KGaA and Dr. Reddy's will co-develop biosimilar drugs, with the Indian generics maker leading early development and testing and the German drugmaker handling late-stage clinical trials, manufacturing and most commercialization. The two will co-commercialize products in the U.S. and share profits. Reuters (6/6) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  Featured Content 

  Food & Agriculture 
  • BASF official: Farmers will see benefits of drought-resistant corn
    Results of an ongoing field test will show the value of BASF and Monsanto's drought-resistant corn DroughtGard, said Peter Eckes, president of the plant science division at BASF. DroughtGard protects growers from yield loss in the event of moderate drought, he said, and criticism of the progress made in the development of drought-resistant biotech corn is based on a "misunderstanding of what the product concept is." Fox Business/Dow Jones Newswires (6/6) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Royal DSM's enzymes get nod for Inbicon cellulosic-ethanol process
    Industrial enzymes supplied by Royal DSM have qualified for the Dong Energy-Inbicon cellulosic-ethanol process after successful testing at a demonstration-scale facility in Kalundborg, Denmark. Royal DSM's enzymes are capable of transforming the cellulose and hemicellulose from biomass into C5 and C6 sugars. DSM is the third enzyme provider to qualify for the Inbicon process after Novozymes and Genencor. (6/5) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

He that cannot forgive others breaks the bridge over which he must pass himself."
--Thomas Fuller,
British churchman and historian

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information